NTLA - Kapitalisasi marang volume dodolan Intellia Therapeutics Inc
Intellia Therapeutics (NTLA) is implementing sustainable synthesis and energy conservation while awaiting CRISPR test results, with the market having already priced in its liquidity and alliances. The company's rolling P/S on the GURU.Markets portal demonstrates a revenue valuation, where the 25.80 mark reflects the latest data. However, the risk of supply chain disruptions and challenges regarding overseas patent protection create a certain vulnerability for the business.
Rincian analitis perusahaan Intellia Corp (NTLA)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Intellia Therapeutics|NTLA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal intelliatx.com|NTLA - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku Intellia Corp|NTLA - Utang jangka dawa perusahaan|Utang jangka cendhak Intellia Therapeutics|Rasio cepet intelliatx.com
- informasi bathi lan kelipatan valuasi:
NTLA - Penghasilan resik|Bathi resik mangsa ngarep Intellia Therapeutics|NTLA - Pangali P/E|Kapitalisasi marang proyeksi bathi Intellia|NTLA - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Intellia Therapeutics|NTLA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Intellia Therapeutics|NTLA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan intelliatx.com|NTLA - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Intellia Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:Intellia Therapeutics, Inc. - NTLA
The business scaling dynamics of Intellia Therapeutics (NTLA) within the CRISPR therapy sector are clearly reflected through the revenue multiple. This indicator compares market capitalization to sales volume, measuring the extent to which the asset's value is inflated relative to current cash flows, which allows investors to assess the balance between the fundamental risks of clinical trials and market expectations for the future commercialization of gene medicines.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
